FY2027 Earnings Forecast for TNXP Issued By Zacks Small Cap

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) - Stock analysts at Zacks Small Cap issued their FY2027 earnings estimates for shares of Tonix Pharmaceuticals in a research report issued to clients and investors on Thursday, April 3rd. Zacks Small Cap analyst D. Bautz forecasts that the company will post earnings of ($0.53) per share for the year. The consensus estimate for Tonix Pharmaceuticals' current full-year earnings is ($1,762.50) per share. Zacks Small Cap also issued estimates for Tonix Pharmaceuticals' FY2027 earnings at ($0.53) EPS.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last issued its quarterly earnings data on Tuesday, March 18th. The company reported ($9.77) EPS for the quarter, missing the consensus estimate of ($6.23) by ($3.54). The firm had revenue of $2.58 million during the quarter, compared to the consensus estimate of $3.20 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%.

Several other research firms have also issued reports on TNXP. Noble Financial reissued an "outperform" rating and issued a $70.00 target price on shares of Tonix Pharmaceuticals in a report on Thursday, March 20th. StockNews.com initiated coverage on shares of Tonix Pharmaceuticals in a research note on Monday, February 10th. They issued a "sell" rating for the company.

Remove Ads

Tonix Pharmaceuticals Stock Performance

Shares of NASDAQ TNXP traded up $2.33 during trading on Friday, hitting $20.13. The company had a trading volume of 1,161,567 shares, compared to its average volume of 735,871. Tonix Pharmaceuticals has a 12 month low of $6.76 and a 12 month high of $672.00. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The firm has a market capitalization of $129.52 million, a P/E ratio of 0.00 and a beta of 1.50. The stock has a 50 day simple moving average of $17.03 and a 200 day simple moving average of $20.29.

Institutional Investors Weigh In On Tonix Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. PFG Investments LLC bought a new position in shares of Tonix Pharmaceuticals during the fourth quarter worth $72,000. Commonwealth Equity Services LLC bought a new position in shares of Tonix Pharmaceuticals during the 4th quarter valued at about $40,000. Geode Capital Management LLC grew its position in shares of Tonix Pharmaceuticals by 1,600.1% during the fourth quarter. Geode Capital Management LLC now owns 1,971,894 shares of the company's stock valued at $650,000 after purchasing an additional 1,855,907 shares in the last quarter. Northern Trust Corp bought a new stake in shares of Tonix Pharmaceuticals in the fourth quarter worth about $162,000. Finally, Jane Street Group LLC lifted its position in shares of Tonix Pharmaceuticals by 5,932.3% in the fourth quarter. Jane Street Group LLC now owns 1,662,682 shares of the company's stock worth $548,000 after buying an additional 1,635,119 shares in the last quarter. Institutional investors own 82.26% of the company's stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.